EMAIL THIS PAGE TO A FRIEND

Diabetes research and clinical practice

Three-month treatment with pioglitazone reduces circulating C1q-binding adiponectin complex to total-adiponectin ratio, without changes in body mass index, in people with type 2 diabetes.


PMID 23142017

Abstract

We measured circulating C1q-binding adiponectin (C1q-APN) levels before and after 3-month treatment with pioglitazone in people with type 2 diabetes. The results indicate 3-month treatment with pioglitazone reduces circulating levels of C1q-APN/total-adiponectin ratio without changes in body mass index.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

C1740 Complement component C1q from human serum, ≥95% (SDS-PAGE)